Can a single nerve injection quiet chronic pelvic pain?

NCT ID NCT07828574

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing whether an ultrasound-guided injection of the local anesthetic articaine plus the steroid triamcinolone near the pudendal nerve reduces pain in adults with pudendal neuralgia, a chronic perineal pain condition. The trial enrolls 120 people whose pain has lasted more than three months and has not improved enough with standard medications or physical therapy. Participants are randomly assigned to receive either the active injection or a saline placebo, and neither they nor the clinicians know which one they get. The main question is whether more people report at least 50% less pain four weeks after the active injection compared with placebo, with follow-up on quality of life, sleep, physical function, pain medication use, and side effects over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A single ultrasound-guided injection of the local anesthetic articaine plus the steroid triamcinolone near the pudendal nerve
What this could lead to
If it works, this could offer a targeted injection option for people whose chronic perineal pain has not responded to standard medications or physical therapy.
What could go wrong
The trial is small and single-center, so results may not hold up in larger or more varied groups. Nerve blocks can cause temporary numbness, soreness, or bleeding, and some people may get little relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Jan 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical Nantes criteria for pudendal neuralgia (all 4 mandatory criteria) * Pain intensity on the Numeric Rating Scale (NRS) greater than 4 out of 10 during the previous 7 days * Pain duration exceeding 3 months * Failure of prior conservative therapy (pregabalin ≥150 mg/day, or gabapentin ≥900 mg/day, or physical therapy) for more than 8 weeks * Age 18 years or older Exclusion Criteria: * Pudendal nerve compression by a space-occupying lesion (tumor, cyst, endometriosis) on pelvic MRI * Coagulopathy (INR \>1.4, platelets \<50×10\^9/L) * Use of anticoagulants or antiplatelet agents that cannot be discontinued 5-7 days before the block (per cardiology consultation) * Active infection at the intended injection site, or systemic infection/sepsis * Allergy to amide-type local anesthetics or corticosteroids * Pregnancy or lactation * Psychiatric conditions precluding understanding of the procedure or completion of questionnaires

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pudendal neuralgia pudendal nerve entrapment chronic pelvic pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kharlampiev Clinic

    Irkutsk, Irkutsk Regio, 664003, Russia